Lupin, Zentiva ink pact to commercialize arthritis drug Certolizumab Pegol
It is indicated for various diseases including heumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis.;
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2025-07-09 09:28 GMT | Update On 2025-07-09 09:28 GMT
Advertisement
Mumbai: Global Pharma major Lupin Limited and Zentiva Group, a pan-European pharmaceutical company, have entered into a license and supply agreement for commercialization of Lupin’s biosimilar Certolizumab Pegol, across multiple markets globally.
Lupin will be responsible for the development, manufacturing and supply of the product within the agreed territories.
Zentiva will oversee commercialization activities outside USA and Canada, predominantly in Europe and CIS markets, where it will leverage its extensive European commercial infrastructure and regulatory expertise. Lupin will undertake commercialization in the remaining regions, including USA and Canada. Both parties will invest in the development of the new biosimilar.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.